Pfizer’s Maraviroc Unanimously Recommended For Accelerated Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
However, members of FDA’s Antiviral Drugs Advisory Committee voice numerous concerns, recommending additional data or analysis for full approval of the CCR5 antagonist.
You may also be interested in...
Pfizer’s Selzentry Wins FDA Approval For HIV
First-in-class CCR5 antagonist will be available by mid-September with a wholesale acquisition cost of $29/day based on twice-a-day dosing, Pfizer tells “The Pink Sheet” DAILY.
Pfizer’s Selzentry Wins FDA Approval For HIV
First-in-class CCR5 antagonist will be available by mid-September with a wholesale acquisition cost of $29/day based on twice-a-day dosing, Pfizer tells “The Pink Sheet” DAILY.
Schering-Plough, Incyte Report Positive Mid-Stage Data For CCR5 Antagonists
Both Schering’s vicriviroc and Incyte’s INCB9471 CCR5 antagonist candidates to treat HIV beat placebo in Phase II trials.